2022 sentyabr: Journal of Clinical Investigation jurnalida chop etilgan tadqiqotga ko'ra, Xyuston universiteti (UH) muhandisi qaysi limfoma bemorlari kimerik antigen retseptorlari (CAR) T-hujayra terapiyasiga ko'proq javob berishini aniqlash mexanizmini kashf etgan bo'lishi mumkin.
Physicians can expedite treatment and maybe save more lives if they are aware of which lymphoma patients react to CAR T-cell therapy. On the other hand, sharing light on people who react poorly and experience serious side effects can open up more possibilities for alternative treatments.
Tadqiqotchilar o'z tadqiqotlarida T hujayra oqsili CD2 va saraton retseptorlari CD58 o'rtasida maxsus aloqani aniqladilar.
In the tumours of lymphoma patients who benefit more from CAR T-hujayra terapiyasi, the CD2 ligand CD58 is expressed at higher levels, according to study author Navin Varadarajan, PhD, MD Anderson professor of chemical and biomolecular engineering.
AT hujayraning CD2 oqsili CD58 bilan bog'lanadi. CD58 CD2 ni faollashtirganda, oqsil aloqada saraton hujayralarini yo'q qila oladigan molekulaga aylanadi.
According to certain recent studies, cancer can be treated by using the patient’s own biological system. One particular technique, called CAR T-hujayra terapiyasi, modifies T cells in the lab so that they will fight cancer cells once they have returned to the body. The consequences of this life-saving procedure could linger for ten years or longer.
CD58 va CD2 o'rtasidagi aloqani yanada chuqurroq tekshirish uchun Varadarajan Texas universiteti MD Anderson saraton markazi tadqiqot guruhi bilan hamkorlik qildi.
Varadarajan Sattva Neelapu (MD Anderson) bilan CAR T davolashdan oldin bemor o'smalarini bo'yash va Varadarajan o'z laboratoriyasida ishlab chiqqan TIMING (Timelapse Imaging Microscopy In Nanowell Grids) usuli yordamida hujayralar ifodasini tekshirish uchun hamkorlik qildi. Ushbu yuqori o'tkazuvchanlik bir hujayrali texnologiya hujayralar qanday harakatlanishi, faollashishi, o'limi, omon qolishi va o'zaro ta'sirini baholashi mumkin.
The scientists discovered that tumours expressing higher amounts of the cancer receptor CD58 responded better to CAR T-hujayra terapiyasi based on the hundreds of interactions they saw between T cells and tumour cells using TIMING.
Varadarajan stated in the news announcement, “We found that CD2 on T cells is related with directional migration. Death and serial killing are accelerated by the interaction between CD2 on T cells and CD58 on limfoma hujayralar.
Varadarajan TIMING texnikasini tijoratlashtirishni maqsad qilgan. U UHda joylashgan CellChorus biznesiga asos solgan. Bemorlar CellChorus-ni o'zlarining maqsadli hujayralarini individual ravishda yuborishlari mumkin; bu hujayralar TIMING testi yordamida tekshiriladi; bu xizmat hali professionallar uchun mavjud emas.
Matbuot relizida Varadarajan shunday dedi: “Biz Xyustondagi inkubator joylashuvimiz boʻlgan Texnologik koʻprikka ega boʻlganimizdan juda baxtiyormiz, mamlakatning eng yaxshi tibbiy muassasasi yonida, dunyoning boshqa koʻplab shaharlarida koʻpaytirish qiyin boʻlgan tibbiyot markazlariga noyob kirish imkoniyati mavjud. mamlakat.
